News    

12 People Hospitalized With Infections From Stem Cell Injections in the USA

Description

How to protect yourself and your loved ones

On December 20, 2018, the New York Times issued an article on the cases of 12 people who got seriously ill following stem cell injections. “The people who became ill after receiving the Genetech (Ed: the Californian company responsible for the contaminated blood products) products had been given injections into their knees, shoul...'

Details
  • 21/12/2018

Hands-on GMP workshop

Description

One of CellCAN's Network Affiliate, the Centre d'Excellence en Thérapie Cellulaire (CETC) in Montreal, was the host of a hands-on GMP workshop from October 14th to 16th, 2018. This exclusive training, organized by CellCAN in partnership with C3i, gave the opportunity to learn the essentials of GMP requirements from experts illustrated by several experiences from actual clinical trials.

Thanks to a mixture of lectures and hands-on training, participants were able to transform kn...'

Details
  • 14/10/2018

Preparing for the Future: Urgent Request for Input

Description

ONLY A FEW DAYS LEFT!!! 

CellCAN attended on June 27th the annual Health Canada Stakeholder Engagement Session: Regulation and Health Innovation. The event was a wonderful opportunity for CellCAN to provide thoughts and feedback pertaining to cell and gene manufacturing regulatory modernization.

At CellCAN we feel your input on the regulatory reform in Canada is of the utmost importance. To do so, please download the documents below. 

Details
  • 23/07/2018

CTSG April 2018 Update

Description

CTSG April 2018 Update - The bi-annual Cell Therapy Stakeholder Group (CTSG) meeting with Health Canada was held on April 24, 2018. The CTSG was previously expanded to include representation from the Regenerative Medicine Alliance of Canada, including the Stem Cell Network (SCN) and the Ontario Institute of Regenerative Medicine (OIRM), in addition to the usual participation from CellCAN, Centre for Commercialization of Regenerative Medicine (CCRM) and the International Society of Cellular T...'

Details
  • 13/07/2018

HC GUI-0100 GCP: CellCAN to Provide Consolidated Feedback on Behalf of Network and Partners

Description

Consultation on “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100: Guidance Document – Part C, Division 5 of the Food and Drug Regulations)' Consultation on “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100: Guidance Document – Part C, Division 5 of the Food and Drug Regulations)

Details
  • 21/12/2017

Connect with a network of Canadian researchers, clinicians, regulatory experts and HQP from coast to coast, through our platforms, workshops and events.

13 NETWORK AFFILIATES. 25 PARTNER ORGANIZATIONS. 181 NETWORK COLLABORATORS.